The FDA is considering a subcutaneous nivolumab formulation for various solid tumors based on promising data from the phase 3 ...
Medical experts discuss a patient case highlighting a 68-year old woman who is uninterested in transplantation and treatment ...
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second ...
Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder ...
A clinical trial to evaluate EIS-12656 in patients with specific types of advanced solid tumors will begin following the ...
In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction ...
Stephen Williams, MD, discusses the phase 3 SunRISe-2 study investigating TAR-200 plus cetrelimab in muscle-invasive bladder ...
Apalutamide with androgen deprivation therapy following radical prostatectomy led to a biochemical recurrence-free survival rate of 100% after 2 years among patients with high-risk prostate cancer.
Finalized breast cancer screening recommendations from the United States Preventive Services Task Force suggest women aged 40 ...
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, ...
Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of ...
Lori J. Wirth, MD, discusses the background and design of the phase 3 SELECT trial of lenvatinib vs placebo for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results